In particular, of the seven patients with intermediate and high risk nodules, one (15%) patient was carrying the MSH2 mutation, two (28%) were carrying the MLH1 mutation, and the two patients who previously had thyroid cancer were carrying the MSH6 and MSH2 mutations, respectively. Here, MSH6 is linked to thyroid gland carcinoma.